JP2004530669A5 - - Google Patents

Download PDF

Info

Publication number
JP2004530669A5
JP2004530669A5 JP2002580978A JP2002580978A JP2004530669A5 JP 2004530669 A5 JP2004530669 A5 JP 2004530669A5 JP 2002580978 A JP2002580978 A JP 2002580978A JP 2002580978 A JP2002580978 A JP 2002580978A JP 2004530669 A5 JP2004530669 A5 JP 2004530669A5
Authority
JP
Japan
Prior art keywords
acid
composition according
composition
cyclooxygenase
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002580978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/011689 external-priority patent/WO2002083177A1/en
Publication of JP2004530669A publication Critical patent/JP2004530669A/ja
Publication of JP2004530669A5 publication Critical patent/JP2004530669A5/ja
Withdrawn legal-status Critical Current

Links

JP2002580978A 2001-04-17 2002-04-12 微細自己乳化医薬組成物 Withdrawn JP2004530669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (2)

Publication Number Publication Date
JP2004530669A JP2004530669A (ja) 2004-10-07
JP2004530669A5 true JP2004530669A5 (enExample) 2005-12-22

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002580978A Withdrawn JP2004530669A (ja) 2001-04-17 2002-04-12 微細自己乳化医薬組成物

Country Status (18)

Country Link
US (1) US20030105141A1 (enExample)
EP (1) EP1379279A1 (enExample)
JP (1) JP2004530669A (enExample)
KR (1) KR20040018355A (enExample)
CN (1) CN1516601A (enExample)
AR (1) AR033221A1 (enExample)
AU (1) AU2002305175B2 (enExample)
BR (1) BR0208994A (enExample)
CA (1) CA2444220A1 (enExample)
CZ (1) CZ20032792A3 (enExample)
EA (1) EA008103B1 (enExample)
IL (1) IL158201A0 (enExample)
MX (1) MXPA03009411A (enExample)
NO (1) NO20034629L (enExample)
NZ (1) NZ528741A (enExample)
PE (1) PE20021145A1 (enExample)
PL (1) PL364524A1 (enExample)
WO (1) WO2002083177A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
JP5296314B2 (ja) * 2003-07-17 2013-09-25 バナー ファーマキャップス,インコーポレイティド 制御放出製剤
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
NZ560712A (en) * 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP5406530B2 (ja) * 2005-10-26 2014-02-05 バナー ファーマキャプス, インコーポレイテッド 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
WO2009040776A1 (en) * 2007-09-27 2009-04-02 Wockhardt Research Centre Self-emulsifying pharmaceutical compositions of rhein or diacerein
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
AU2011260615B2 (en) * 2010-06-02 2016-11-17 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
CN110292575B (zh) * 2011-10-18 2022-05-13 株式会社AskAt 药物组合物
MX377877B (es) * 2013-01-14 2025-03-11 Infirst Healthcare Ltd Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CN105120900A (zh) * 2013-02-04 2015-12-02 因佛斯特医疗有限公司 用于治疗慢性炎症和炎性疾病的组合物及方法
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
SG11201811050PA (en) 2016-07-05 2019-01-30 Golden Renewable Energy Llc System and process for converting waste plastic into fuel
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
CA2415697A1 (en) * 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Similar Documents

Publication Publication Date Title
JP2014505660A5 (enExample)
JP2009541223A5 (enExample)
JP2019500387A5 (enExample)
RU2009138500A (ru) 4, -о-замещенные изоиндолиновые производные и содержащие их композиции и способы их применения
JP2009524675A5 (enExample)
RU2004130291A (ru) Способ получения самостоятельно мелко эмульгирующейся фармацевтичес кой композиции
JP2005500363A5 (enExample)
JP2015535247A5 (enExample)
JP2020507589A5 (enExample)
JP2014530900A5 (enExample)
JP6261011B2 (ja) 眼疾患処置薬
JP2020524178A5 (enExample)
JP2020533352A5 (enExample)
RU2009136592A (ru) Терапевтические агенты
JP2015510930A5 (enExample)
JP2020505354A5 (enExample)
JP2011507879A5 (enExample)
JP2008538784A (ja) 膀胱機能を調節するための方法
JP2013522368A5 (enExample)
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2012510985A5 (enExample)
JP2017515899A5 (enExample)
JP2019516709A5 (enExample)
JP2018522049A5 (enExample)
ZA202309953B (en) Novel heterocyclic compounds and their use